August GEM Recognizes Outstanding Paper Advancing Precision Immunotherapy for Type 1 Diabetes
The University of Utah College of Pharmacy has selected “Immune context governs stage-specific responses to depleting anti-PD-1 antibody in type 1 diabetes” as its August GEM: Outstanding Paper, recognizing research from Associate Professor Mingnan Chen, PhD, (Molecular Pharmaceutics) and collaborators. Published in Cell Biomaterials in May 2026, the study advances a potential new therapeutic strategy for type 1 diabetes (T1D) while highlighting an important principle for autoimmune therapy: the effectiveness of treatment can depend strongly on disease stage and immune context.
In preclinical models, the team found that a depleting anti-PD-1 antibody delayed diabetes when given at an early disease stage but worsened disease when administered later. By combining single-cell analysis with immunologic and therapeutic studies, the researchers identified macrophages as important contributors to these stage-dependent responses. The broader significance is clear: successful immunotherapy may require not only selecting the right therapeutic target, but also identifying the right patients and the right time for treatment. These findings therefore support a more precise and personalized approach to autoimmune therapy.
The study was led by graduate student Yujia Zhai (Chen Lab), whose dissertation research initiated and drove this project. Chen laboratory members Shuyun Dong, Lauren C. Naatz, and Tianxiao Zhang contributed to the experimental studies. Key collaborations brought complementary expertise to the project. Xiangyang Ye, PhD (Pharmacotherapy) contributed expertise in biostatistics and quantitative analysis; Dean Tantin, PhD (Pathology) brought expertise in molecular immunology and immune-cell biology; Tallulah Andrews, DPhil (Biochemistry, University of Western Ontario) contributed expertise in computational analysis of single-cell and spatial omics data.
Together, this team transformed an unexpected therapeutic observation into a mechanistic framework with direct implications for precision medicine. The work also established a foundation for continued investigation: in February 2026, Chen and collaborators received an NIH/NIAID R01 to further examine how autoimmune immune environments influence responses to depleting anti-PD-1 antibodies.
